COVID-19 Impact on Sysmex Corp's Revenue and Operations (Medical Devices)

Summary

Sysmex Corporation (Sysmex), is a leading diagnostics solutions company that offers hematology, urinalysis, information systems, and flow cytometry testing technology, headquartered in Japan with global manufacturing and sales reach. Sysmex’s product range include diagnostic solutions for hematology, urinalysis, and hemostasis as well as tools to efficiently manage laboratory information and workflows. The report, COVID-19 Impact on Sysmex Corp's Revenue and Operations (Medical Devices) presents a deep dive analysis into how Sysmex Corp is placed to respond to the COVID-19 crisis, by examining its sector performance and competitiveness.

Deep dive analysis into how Sysmex Corp is placed to respond to the COVID-19 crisis, by examining its sector performance and competitiveness.

Key Highlights

• The global spread of COVID-19 has put much of Sysmex's business at risk, especially since the company has a significant presence in Asia Pacific (APAC), the US and Europe.
• Sysmex reported a 3.9% decrease in year-over-year (YoY) revenues during their fiscal second quarter ending on September 30th 2020, primarily due to decreased instrument and reagent sales both domestically and internationally. The publisher expects that sales will continue to recover during the remainder of 2020, although APAC (excluding China) may continue to struggle reaching positive YoY growth.

Scope

The report provides a comprehensive analysis of the impact of COVID-19 on Sysmex Corp -

• It provides insights on Sysmex Corp's exposure to the regions and businesses impacted by the COVID-19 outbreak.
• It offers an overview of the company’s revenue impact by region and market for 2020 due to the COVID-19 outbreak.

Reasons to Buy

• An overview of how Sysmex Corp will be affected by the COVID-19 pandemic.